Seeking Alpha

More on AbbVie (ABBV -0.8%) guidance: expects 2013 sales of above $18B vs consensus of $18.2B...

More on AbbVie (ABBV -0.8%) guidance: expects 2013 sales of above $18B vs consensus of $18.2B and $18.1B last year; forecasts Q1 adjusted EPS of $0.64-$0.66 vs $0.69. Predicts low double-digit Humira growth vs 17% last year, although Abbot was known for conservative projections. AbbVie sees additional $1B in revenue over next 5 years from emerging markets; interested in small "tuck in" acquisitions. Forecasts that new drugs will drive growth from H2 2015.

Check out Seeking Alpha’s new Earnings Center »

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs